News | April 25, 2025
We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
Bayer expects 2025 to be the most difficult year of its turnaround
Bayer expects 2025 to be the most difficult year of its turnaround
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Arth by Emcure is a specialized range of supplements designed to address the unique health and wellness needs of women, enabling them to lead healthier and happier lives across all stages
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Report highlights significant improvements in adolescent well-being in India
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
Subscribe To Our Newsletter & Stay Updated
